

Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

<https://marketpublishers.com/r/A883B11C3E4EEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: A883B11C3E4EEN

Abstracts

The 7 major Amyotrophic Lateral Sclerosis (ALS) markets reached a value of US\$ 494.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 715.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.4% during 2024-2034.

Amyotrophic Lateral Sclerosis (ALS) market is currently driven by factors such as a rising geriatric population, a strong drug pipeline that have a good efficacy and safety profile and improving diagnosis and drug treatment rates. Amyotrophic lateral sclerosis is a rare neurological disorder that predominantly affects the nerve cells (neurons) responsible for controlling voluntary muscle movement. Although the indication can happen at any age, symptoms most commonly appear during the ages of 55 and 75. With the geriatric population expected to increase significantly over the long term, we expect the incidence of Amyotrophic Lateral Sclerosis to increase significantly over the next few years.

ALS belongs to a broader group of disorders known as motor neuron diseases, that are caused due to the gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend throughout the body from the brain to the spinal cord and to muscles. As motor neurons deteriorate, they cease sending messages to the muscles. As a result, the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, this results in the brain losing its ability to initiate and control voluntary movements. Early symptoms of ALS normally include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and patients lose their strength and the ability to speak, eat, move, and even breathe. The indication is progressive, resulting in the symptoms getting worse over time.

IMARC Group's new report "Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Amyotrophic Lateral Sclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Amyotrophic Lateral Sclerosis market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Amyotrophic Lateral Sclerosis across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Amyotrophic Lateral Sclerosis and represents the largest market for Amyotrophic Lateral Sclerosis treatment. Furthermore, the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Amyotrophic Lateral Sclerosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, Current, and Future Epidemiology Scenario

Historical, Current, and Future Performance of the Amyotrophic Lateral Sclerosis

Market

Historical, Current, and Future Performance of Various Therapeutic Categories in the Amyotrophic Lateral Sclerosis Market

Sales of Various Drugs Across the Amyotrophic Lateral Sclerosis Market

Reimbursement Scenario in the Amyotrophic Lateral Sclerosis Market

Competitive Landscape:

This report also provides a detailed analysis of the current Amyotrophic Lateral Sclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Amyotrophic Lateral Sclerosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?

What was the country-wise size of the Amyotrophic Lateral Sclerosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Amyotrophic Lateral Sclerosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the Amyotrophic Lateral Sclerosis market?

Epidemiology Insights

What is the size of the Amyotrophic Lateral Sclerosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) of Amyotrophic Lateral Sclerosis across the seven major markets?

What are the key factors driving the epidemiological trend of Amyotrophic Lateral Sclerosis?

What will be the growth rate of Amyotrophic Lateral Sclerosis patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current marketed Amyotrophic Lateral Sclerosis drugs and what are their market performance?

What are the key pipeline Amyotrophic Lateral Sclerosis drugs and how are they expected to perform in the coming years?

How safe are the currently marketed Amyotrophic Lateral Sclerosis drugs and what are their efficacies?

How safe are the late-stage pipeline Amyotrophic Lateral Sclerosis drugs and what are their efficacies?

What are the current treatment guidelines for Amyotrophic Lateral Sclerosis drugs across the seven major markets?

Who are the key companies in the Amyotrophic Lateral Sclerosis market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Amyotrophic Lateral Sclerosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 AMYOTROPHIC LATERAL SCLEROSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.3 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.4 Competitive Intelligence

5 AMYOTROPHIC LATERAL SCLEROSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 AMYOTROPHIC LATERAL SCLEROSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

8 AMYOTROPHIC LATERAL SCLEROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Amyotrophic Lateral Sclerosis Guidelines, Management and Treatment

8.2 Amyotrophic Lateral Sclerosis Treatment Algorithm

9 AMYOTROPHIC LATERAL SCLEROSIS - UNMET NEEDS

10 AMYOTROPHIC LATERAL SCLEROSIS - KEY ENDPOINTS OF TREATMENT

11 AMYOTROPHIC LATERAL SCLEROSIS - MARKETING PRODUCTS

11.1 List of Amyotrophic Lateral Sclerosis Marketed Drugs Across the Top 7 Markets

11.1.1 Drug Name - Company Name

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 AMYOTROPHIC LATERAL SCLEROSIS - PIPELINE DRUGS

12.1 List of Amyotrophic Lateral Sclerosis Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name - Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. AMYOTROPHIC LATERAL SCLEROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 AMYOTROPHIC LATERAL SCLEROSIS - MARKET SCENARIO

- 14.1 Market Scenario - Key Insights
- 14.2 Market Scenario - Top 7 Markets
 - 14.2.1 Amyotrophic Lateral Sclerosis - Market Size
 - 14.2.1.1 Market Size (2018-2023)
 - 14.2.1.2 Market Forecast (2024-2034)
 - 14.2.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
 - 14.2.2.1 Market Size by Therapies (2018-2023)
 - 14.2.2.2 Market Forecast by Therapies (2024-2034)
- 14.3 Market Scenario - United States
 - 14.3.1 Amyotrophic Lateral Sclerosis - Market Size
 - 14.3.1.1 Market Size (2018-2023)
 - 14.3.1.2 Market Forecast (2024-2034)
 - 14.3.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
 - 14.3.2.1 Market Size by Therapies (2018-2023)
 - 14.3.2.2 Market Forecast by Therapies (2024-2034)
 - 14.3.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

14.4 Market Scenario - Germany

14.4.1 Amyotrophic Lateral Sclerosis - Market Size

14.4.1.1 Market Size (2018-2023)

14.4.1.2 Market Forecast (2024-2034)

14.4.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies

14.4.2.1 Market Size by Therapies (2018-2023)

14.4.2.2 Market Forecast by Therapies (2024-2034)

14.4.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

14.5 Market Scenario - France

14.5.1 Amyotrophic Lateral Sclerosis - Market Size

14.5.1.1 Market Size (2018-2023)

14.5.1.2 Market Forecast (2024-2034)

14.5.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies

14.5.2.1 Market Size by Therapies (2018-2023)

14.5.2.2 Market Forecast by Therapies (2024-2034)

14.5.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

14.6 Market Scenario - United Kingdom

14.6.1 Amyotrophic Lateral Sclerosis - Market Size

14.6.1.1 Market Size (2018-2023)

14.6.1.2 Market Forecast (2024-2034)

14.6.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies

14.6.2.1 Market Size by Therapies (2018-2023)

14.6.2.2 Market Forecast by Therapies (2024-2034)

14.6.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

14.7 Market Scenario - Italy

14.7.1 Amyotrophic Lateral Sclerosis - Market Size

14.7.1.1 Market Size (2018-2023)

14.7.1.2 Market Forecast (2024-2034)

14.7.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies

14.7.2.1 Market Size by Therapies (2018-2023)

14.7.2.2 Market Forecast by Therapies (2024-2034)

14.7.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

14.8 Market Scenario - Spain

14.8.1 Amyotrophic Lateral Sclerosis - Market Size

14.8.1.1 Market Size (2018-2023)

14.8.1.2 Market Forecast (2024-2034)

14.8.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies

14.8.2.1 Market Size by Therapies (2018-2023)

14.8.2.2 Market Forecast by Therapies (2024-2034)

- 14.8.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
 - 14.9.1 Amyotrophic Lateral Sclerosis - Market Size
 - 14.9.1.1 Market Size (2018-2023)
 - 14.9.1.2 Market Forecast (2024-2034)
 - 14.9.2 Amyotrophic Lateral Sclerosis - Market Size by Therapies
 - 14.9.2.1 Market Size by Therapies (2018-2023)
 - 14.9.2.2 Market Forecast by Therapies (2024-2034)
 - 14.9.3 Amyotrophic Lateral Sclerosis - Access and Reimbursement Overview

15 AMYOTROPHIC LATERAL SCLEROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 AMYOTROPHIC LATERAL SCLEROSIS MARKET - SWOT ANALYSIS

- 16.1 Strengths
- 16.2 Weaknesses
- 16.3 Opportunities
- 16.4 Threats

17 APPENDIX

I would like to order

Product name: Amyotrophic Lateral Sclerosis (ALS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A883B11C3E4EEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A883B11C3E4EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

